Sign In
Buy PAVM
$4.68
-0.230 (-4.68%)
At Close: Jun 23, 2026
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
08:01am, Tuesday, 26'th Aug 2025
Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasia Lucid Diagnostics to collaborate with PAVmed as a
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
08:00am, Thursday, 14'th Aug 2025
Lucid processed 2,756 EsoGuard® 2Q25 tests, recognized revenue of $1.2 million,and secured CAC meeting on Medicare LCD for EsoGuard to be held on September4 Veris Health completed 2Q25 financing, rel
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
08:00am, Wednesday, 13'th Aug 2025
Processed 2,756 EsoGuard® tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma cash and extending runway well past upcoming reimbursement milestones Mul
Lucid Diagnostics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 05'th Aug 2025
NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed
PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025
08:01am, Thursday, 31'st Jul 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 31, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technolo
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
08:01am, Wednesday, 30'th Jul 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention m
PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
08:00am, Wednesday, 30'th Jul 2025
NEW YORK , July 30, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnosti
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
07:31am, Wednesday, 16'th Jul 2025
Virtual public CAC meeting to be held September 4, 2025, at 2:00 p.m. ET NEW YORK , July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage
PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing
08:01am, Tuesday, 24'th Jun 2025
Private placement yields $2.5 million from the sale of Veris Health common stock at a $35 million pre-money valuation. NEW YORK , June 24, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or
Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK , June 18, 2025 /PR
Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK , June 3, 2025 /PRNewswire/ -- PAV
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
07:31am, Tuesday, 27'th May 2025
NEW YORK , May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed
PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript
01:58pm, Thursday, 15'th May 2025
PAVmed Inc. (NASDAQ:PAVM ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of Investor Relations Lishan Aklog - Chairman and Chief Executive
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
08:01am, Thursday, 15'th May 2025
Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
08:01am, Wednesday, 14'th May 2025
Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25 Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in pr
